InvestorsHub Logo
Followers 4054
Posts 151292
Boards Moderated 4
Alias Born 08/05/2009

Re: Golden Cross post# 6718

Thursday, 06/27/2019 8:08:48 AM

Thursday, June 27, 2019 8:08:48 AM

Post# of 8461

“The accelerated approval pathway, combined with the strategic partnership we announced today with Catalent Biologics, allow us to efficiently and cost effectively complete the clinical development of NanoFlu through BLA and licensure,” said Stanley C. Erck, President and Chief Executive Officer of Novavax. “The Catalent deal provides an $18 million cash infusion and flexible manufacturing capacity, supported by the experienced professionals transferred from Novavax to Catalent.”



NVAX NEWS https://finance.yahoo.com/news/novavax-confirms-accelerated-approval-pathway-110000464.html

Always consult an Investment Professional, my posts are my own opinions, and not for investing decisions

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NVAX News